TELA Bio, Inc.

NASDAQ:TELA

Medical - Devices

Healthcare
$1.14 +8.26%

+$0.09 today

Market cap
$51.00M
Beta
1.36
P/E (TTM)
-1.5
EPS (TTM)
-$0.72
52W Low $0.50High $1.69

Volume 0.22M

Average 0.17M

TELA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

TELA Bio, Inc.NASDAQ: TELA

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q2 FY2026 weighted avg shares of 57.41M shares rose 26.6% year over year, behind the +36.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +42.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +26.6% toward the trailing-twelve-month pace of +36.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
57.41M+0.3% QoQ
Last fiscal yearDec 2025
46.95M+64.6% YoY
LTMJun 2026
52.94M+36.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.6%——
1 year+64.6%——
3-year CAGR+42.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
46.95M USD
Year-over-year change
+64.6%
4-year CAGR
+34.2%

Weighted Avg Shares vs competitors

How TELA compares with its peers on the latest reported figures

  • TELA's LTM Jun 2026 weighted avg shares of 52.94M shares is the 3rd highest of the 9 companies compared; the peer median is 21.21M shares.
  • Its year-over-year change of +36.3% is the 7th highest of 9, against a peer median of +65.6%.
  • Over three fiscal years its annual growth of +42.4% compares with a peer median of +10.9%.
TELA Competitors Peer median
Weighted Avg Shares for TELA and competitors
Company Period LTM YoY 3-year CAGR
EQEquillium, Inc.LTM Mar 202664.9M +83.3%+39.7%
OTLKOutlook Therapeutics, Inc.LTM Mar 202653.45M +120.6%+48.6%
TELATELA Bio, Inc.LTM Jun 202652.94M +36.3%+42.4%
MDAISpectral AI, Inc.LTM Mar 202628.45M +47.3%+14.0%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202626.06M +115.3%-31.2%
SRTSSensus Healthcare, Inc.LTM Mar 202616.36M +0.3%-0.3%
COEPCoeptis Therapeutics, Inc.LTM Mar 20264.68M -77.3%-33.3%
CUECue Biopharma, Inc.LTM Mar 20263.74M +79.5%+38.5%
SPRBSpruce Biosciences, Inc.LTM Mar 2026827.01K +51.8%+7.8%
Peer median (excluding TELA) 21.21M+65.6%+10.9%

Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue29.46M41.42M58.45M69.3M80.28M
Cost of Revenue10.65M14.37M18.34M22.81M25.93M
Gross Profit18.81M27.04M40.11M46.49M54.34M
Gross Margin63.9%65.3%68.6%67.1%67.7%
Research & Development6.74M8.94M9.62M8.81M9.22M
Selling, General & Admin41.52M57.11M74.57M79.37M78.88M
Operating Expenses48.26M66.05M84.19M80.6M88.1M
Depreciation & Amortization535K1.19M808K1.01M1.01M
EBITDA(29.14M)(39.06M)(40.63M)(31.68M)(32.35M)
EBITDA Margin-98.9%-94.3%-69.5%-45.7%-40.3%
Operating Income(29.45M)(39.01M)(44.08M)(34.12M)(33.76M)
Operating Margin-100.0%-94.2%-75.4%-49.2%-42.0%
Interest Income00000
Interest Expense3.6M4.05M5.22M5.29M5.25M
Other Income / Expenses(3.83M)(5.29M)(2.59M)(3.87M)(4.85M)
Income Before Tax(33.28M)(44.3M)(46.66M)(37.99M)(38.6M)
Pre-Tax Margin-112.9%-106.9%-79.8%-54.8%-48.1%
Income Tax Expense000(144K)230K
Net Income(33.28M)(44.3M)(46.66M)(37.84M)(38.83M)
Net Margin-112.9%-106.9%-79.8%-54.6%-48.4%
EPS (Basic)(2.30)(2.73)(2.04)(1.33)(0.83)
EPS (Diluted)(2.30)(2.73)(2.04)(1.33)(0.83)
Weighted Avg Shares14.47M16.27M22.87M28.53M46.95M
Weighted Avg Shares (Diluted)14.47M16.27M22.87M28.53M46.95M

TELA Bio, Inc.

NASDAQ:TELA

Intrinsic Alpha fair value

Locked

Current Price

$1.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.